by Ryan Cross on May 5th, 2025 Topas Therapeutics, a small German biotech company attempting to quell overactive immune systems, has revealed the first data
– Data published in Obesity journal show enhanced weight loss effect of NT-0796 when combined with semaglutide in preclinical obesity model– Obese state completely reversed
Apellis Pharmaceuticals, Inc. (APLS) has announced the immediate appointment of Craig Wheeler to its Board of Directors. Wheeler, the founder and CEO of Headwaters Biotech
Highlights LONDON, UK and Boston, MA, 7 April 2025 – Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces
WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted
Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as Chair Cambridge, UK,
WALTHAM, Mass. October 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT
29 October 2024, Dr. Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the
Hamburg, Germany, October 15th, 2024 – Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with
Brighton, UK, 26 September 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceuticalcompany dedicated to the discovery and development of novel therapies to improve the lives of